News Abcuro raises $200m to take muscle disease drug to market Abcuro has raised $200m in financing that should allow it to complete a pivotal trial of ulviprubart for rare disease inclusion body myositis (IBM).
News Abcuro raises $155m for KLRG1 drug trial Abcuro has raised $155 million in an oversubscribed second financing round that will fund its phase 2/3 trial of lead drug ABC008 for the treatment of inclusion body myosi